insulin drugs glp 1 receptor agaonist market GLP-1 Agonists Report 2025-2033, By Product, Molecule, and Geo Glucagon-like Peptide-1 (GLP-1) Agonists Market
Description
[DOI] [PubMed] [Google Scholar] 106.Nauck M.A., Frossard J.L., Barkin J.S., Anglin G., Hensley I.E., Harper K.D
-agonists-market-key-insight.png)
doi: 10.1016/j.cgh.2024.03.006
GLP-1, a 36-amino acid peptide, is produced in enteroendocrine L-cells of the distal small bowel and colon (92)
13 Given these multiple actions, in pediatric models, GLP-1R activation may directly interfere with metabolic plasticity, cellular differentiation, and tissue remodeling, requiring caution regarding potential off-target effects during growth and development
Samms RJ, Zhang G, He W, et al
Top 20 Companies Leading the Global Glucagon-Like Peptide-1 agonists Market Novo Nordisk Eli Lilly and Company Sanofi AstraZeneca Pfizer Inc
